Phase II study on DON in patients with previously treated advanced lung cancer.
D000230:Adenocarcinoma / Q000188:drug therapy; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use*; D001391:Azo Compounds / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy; D003980:Diazooxonorleucine / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis
D000903:Antibiotics, Antineoplastic; D001391:Azo Compounds; D003980:Diazooxonorleucine